U.S. Global Investors (USGI)’s AbbVie ABBV Stock Holding History

U.S. Global Investors (USGI)’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-5,361	Closed	-$390K	–	159
2019 Q2	$390K	Sell	5,361 -9,227	-63%	-$725K	0.2%	122
2019 Q1	$1.18M	Sell	14,588 -3,631	-20%	-$297K	0.56%	47
2018 Q4	$1.68M	Buy	18,219 +13,830	+315%	+$1.22M	0.97%	25
2018 Q3	$415K	Buy	+4,389	New	+$416K	0.2%	104
2017 Q4	–	Sell	-21,363	Closed	-$1.9M	–	120
2017 Q3	$1.9M	Sell	21,363 -6,300	-23%	-$480K	0.56%	36
2017 Q2	$2.01M	Buy	+27,663	New	+$1.86M	0.69%	35
2016 Q4	–	Sell	-14,700	Closed	-$927K	–	149
2016 Q3	$927K	Sell	14,700 -3,300	-18%	-$214K	0.44%	72
2016 Q2	$1.11M	Buy	+18,000	New	+$1.1M	0.61%	65
2015 Q4	–	Sell	-6,500	Closed	-$354K	–	247
2015 Q3	$354K	Buy	6,500 +3,100	+91%	+$202K	0.19%	114
2015 Q2	$228K	Buy	+3,400	New	+$222K	0.09%	200
2014 Q2	–	Sell	-11,000	Closed	-$565K	–	290
2014 Q1	$565K	Buy	11,000 +5,500	+100%	+$278K	0.09%	172
2013 Q4	$290K	Hold	5,500	–	–	0.05%	200
2013 Q3	$246K	Buy	+5,500	New	+$244K	0.04%	196

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

U.S. Global Investors (USGI)'s ABBV Position: Q3 2019 in Review

U.S. Global Investors (USGI) sold out of AbbVie (ABBV) in Q3 2019, closing a stake of 5,361 shares — an estimated $390K sold.

U.S. Global Investors (USGI) first reported a position in ABBV in Q3 2013 and held it in 13 quarters. The position peaked at $2.01M in Q2 2017. 2,003 funds tracked by Wall St. Rank hold ABBV as of Q3 2019.

U.S. Global Investors (USGI) reported no remaining AbbVie position as of Q3 2019 after selling out during the quarter.
U.S. Global Investors (USGI) sold 5,361 AbbVie shares in Q3 2019, an estimated $390K.
U.S. Global Investors (USGI) first reported a position in AbbVie in Q3 2013 and held it in 13 quarters.
U.S. Global Investors (USGI)'s AbbVie position peaked at $2.01M in Q2 2017.
2,003 funds tracked by Wall St. Rank held AbbVie as of Q3 2019.

Based on U.S. Global Investors (USGI)'s 13F filing for Q3 2019, filed 12 Nov 2019.